- Mixed lineage kinase domain‑like protein (MLKL) is the terminal executioner of necroptosis, a regulated form of necrotic cell death characterised by membrane rupture, cellular swelling and release of inflammatory mediators. Unlike apoptosis, which relies on caspase activation and maintains membrane integrity, necroptosis culminates in catastrophic membrane disruption driven directly by MLKL. This makes MLKL a unique effector whose activation marks the irreversible commitment to necroptotic death.
- MLKL is a pseudokinase, meaning it resembles a kinase structurally but lacks catalytic activity. Instead, MLKL functions as a regulated scaffold that undergoes conformational changes upon phosphorylation by RIPK3. MLKL contains two major regions: an N‑terminal four‑helix bundle (4HB) domain responsible for membrane binding and disruption, and a C‑terminal pseudokinase domain that controls activation. In resting cells, MLKL is maintained in an inactive conformation, preventing accidental membrane damage.
- Necroptosis is initiated when death receptors such as TNFR1 are activated under conditions where caspase‑8 is inhibited. This allows RIPK1 and RIPK3 to assemble into the necrosome, where RIPK3 phosphorylates MLKL at conserved serine/threonine residues. Phosphorylation triggers MLKL oligomerisation, exposing the 4HB domain and enabling MLKL to translocate to cellular membranes.
- Once activated, MLKL moves to the plasma membrane, endosomal membranes and other intracellular compartments. At the plasma membrane, MLKL oligomers insert into lipid bilayers, forming disruptive pores or destabilising membrane structure. This causes ionic imbalance, osmotic swelling, membrane rupture and release of DAMPs (damage‑associated molecular patterns), including HMGB1, ATP and nucleic acids. These signals activate innate immunity and amplify inflammation.
- MLKL’s activity is tightly regulated to prevent unintended necroptosis. Post‑translational modifications, chaperone interactions and membrane lipid composition influence MLKL activation and localisation. Cellular stress pathways such as oxidative stress and autophagy modulate MLKL turnover and necrosome stability. Crosstalk with apoptosis ensures necroptosis is triggered only when apoptotic machinery is compromised.
- MLKL plays important roles in physiology and disease. During viral infection, many viruses inhibit caspase‑8 to block apoptosis; MLKL‑mediated necroptosis acts as a fail‑safe mechanism to eliminate infected cells. In inflammatory diseases, excessive MLKL activation contributes to tissue damage, cytokine release and chronic inflammation. MLKL‑driven necroptosis is implicated in neurodegeneration, ischemia–reperfusion injury, pancreatitis, inflammatory bowel disease and certain cancers.
- Because MLKL is the final executioner of necroptosis, it is an attractive therapeutic target. Inhibiting MLKL may reduce tissue damage in inflammatory and degenerative diseases, whereas activating MLKL could enhance clearance of infected or malignant cells. Understanding MLKL’s structural dynamics, membrane interactions and regulatory mechanisms remains a major focus of necroptosis research.
- In summary, MLKL is the terminal effector of necroptosis, activated by RIPK3 phosphorylation and responsible for membrane rupture and inflammatory cell death. Through oligomerisation, membrane translocation and pore formation, MLKL executes necroptosis and shapes immune responses. Its central role in regulated necrosis makes MLKL a key determinant of inflammation, host defence and disease progression.
